✦ LIBER ✦

Imatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia

✍ Scribed by P. Bizargity; C. Adıgüzel; G. Ozilhan; M. Bayık; E. Eksioglu-Demiralp

Book ID: 108701653
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 37 KB
Volume: 27
Category: Article
ISSN: 1751-5521
DOI: 10.1111/j.1365-2257.2004.00657.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib does not impair specific antitu

Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia

✍ Bocchia, M; Abruzzese, E; Forconi, F; Ippoliti, M; Trawinska, M M; Pirrotta, M T 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 68 KB

Imatinib use either pre- or post-allogen

Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients

✍ Burke, M J; Trotz, B; Luo, X; Weisdorf, D J; Baker, K S; Wagner, J E; Verneris, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 200 KB

Multicenter prospective trial evaluating

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?

✍ Yoshinobu Kanda; Shinichiro Okamoto; Tetsuzo Tauchi; Masahiro Kizaki; Koiti Inok 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japan

Nitric oxide synthase inhibition does no

Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites

✍ Helle C Thiesson; Ole Skøtt; Bente Jespersen; Ove B Schaffalitzky de Muckadell 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 107 KB

Granulocyte-macrophage colony stimulatin

Granulocyte-macrophage colony stimulating factor does not improve neutrophil oxidative metabolism in a patient with variant X-linked chronic granulomatous disease

✍ T. J. Mühlebach; H. J. Feickert; K. Welte; R. A. Seger 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 438 KB

Prior treatment with the tyrosine kinase

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

✍ Shimoni, A; Leiba, M; Schleuning, M; Martineau, G; Renaud, M; Koren-Michowitz, M 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB